IGM Biosciences Dividendo

Dividendo criteri di controllo 0/6

IGM Biosciences non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore	1.9%
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Utile per azione	-US$3.72
Previsione del rendimento del dividendo	0%

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

Jan 05

IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business

Sep 23

IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates

Aug 29

IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M

Aug 08

We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

Jun 09

IGM Biosciences: Interesting Science, Poor Trial Data

Feb 23

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?

Feb 17

Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

Sep 07

IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans

May 25

IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans

Feb 08

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di IGMS siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di IGMS siano aumentati.

Rendimento dei dividendi rispetto al mercato

IGM Biosciences Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di IGMS rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (IGMS)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.4%
Media del settore (Biotechs)	1.9%
Analista previsionale (IGMS) (fino a 3 anni)	0%

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di IGMS rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di IGMS rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di IGMS per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché IGMS non ha segnalato alcun pagamento.

IGM Biosciences Dividendo

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sui dividendi

Recent updates

We're Not Very Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

Consensus revenue estimates decrease by 74%

Price target decreased by 13% to US$19.10

IGM Biosciences, Inc. Announces Chief Executive Officer Changes

IGM Biosciences: Waiting For Godot

Consensus revenue estimates increase by 281%

Consensus revenue estimates fall by 95%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

IGM Biosciences, Inc. Provides Pipeline Updates

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 15%

Consensus revenue estimates increase by 1,210%

IGM Biosciences: Unlikely To Move The Needle Again In 2024

First quarter 2024 earnings released: US$0.83 loss per share (vs US$1.33 loss in 1Q 2023)

IGM Biosciences, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?

IGM Biosciences, Inc., Annual General Meeting, Jun 11, 2024

New major risk - Share price stability

CEO, President & Director recently sold US$90k worth of stock

Consensus EPS estimates upgraded to US$3.26 loss

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points

Igm Biosciences, Inc. to Reduce its Workforce by Approximately 22%

Consensus revenue estimates decrease by 13%, EPS upgraded

We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

IGM Biosciences, Inc. Announces Board Changes

Price target decreased by 7.8% to US$30.09

New minor risk - Shareholder dilution

IGM Biosciences, Inc. announced a financing transaction

IGM Biosciences, Inc. Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis

Consensus revenue estimates decrease by 43%, EPS upgraded

We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn

Consensus revenue estimates decrease by 50%

Price target decreased by 17% to US$32.64

IGM Biosciences Initiates First-In-Human Clinical Trial of Igm-7354 in Solid Tumors

IGM Biosciences Announces Update on Igm-8444 Phase 1 Trial and Future Clinical Development

Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

CEO, President & Director recently sold US$235k worth of stock

CEO, President & Director notifies of intention to sell stock

Independent Director recently bought US$1.0m worth of stock

Insufficient new directors

Independent Director recently bought US$1.0m worth of stock

Chief Scientific Officer exercised options and sold US$548k worth of stock

Independent Chairman of the Board recently bought US$140k worth of stock

IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business

Chief Scientific Officer exercised options and sold US$460k worth of stock

IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates

Chief Scientific Officer exercised options and sold US$531k worth of stock

Price target decreased to US$43.78

Consensus revenue estimates fall by 98%

IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M

Insufficient new directors

We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

IGM Biosciences, Inc. Appoints Steven Weber as Principal Accounting Officer

Independent Director recently bought US$234k worth of stock

Consensus revenue estimates fall by 86%

Price target decreased to US$52.78

Chief Scientific Officer exercised options and sold US$60k worth of stock

Independent Director recently bought US$1.4m worth of stock

Price target decreased to US$52.78

Chief Scientific Officer exercised options and sold US$207k worth of stock

Price target decreased to US$57.89

IGM Biosciences: Interesting Science, Poor Trial Data

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?

IGM Biosciences, Inc. Advances Novel Antibody IGM-6268 into Clinical Trials for the Treatment and Prevention of COVID-19

Price target decreased to US$67.78

Price target decreased to US$85.33

IGM Biosciences, Inc. Presents Clinical Data from IGM-2323 in Patients with Advanced B Cell Malignancies at 2021 American Society of Hematology Annual Meeting

Chief Scientific Officer exercised options and sold US$124k worth of stock

Chief Scientific Officer exercised options and sold US$160k worth of stock

Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

Chief Scientific Officer exercised options and sold US$176k worth of stock